Vedran Radojcic is an Oncology physician affiliated with Huntsman Cancer Institute. OpenAlex indexes 87 publications with 1,591 citations (h-index 18); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 E Medical Center Dr
7th Floor Cs Mott Childrens Hospital Recp B
Ann Arbor, MI 481094257
Telephone
734-936-9814Provider last certified this registry record 12 Nov 2021.
Clinical trials
- A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD
Sponsor: Syndax Pharmaceuticals
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Syndax Pharmaceuticals, Inc.Program year20252 payments
- Regeneron Pharmaceuticals, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The Effects of Prior Lines of Therapy on Clinical Outcomes for Patients with Chronic Graft-Versus-Host Disease Receiving Axatilimab: A Post Hoc Analysis of Agave-201
Biology of Blood and Marrow Transplantation
2025 - Kinetics and Management of Hepatic Laboratory Elevations Associated with Axatilimab in the Agave-201 Study
Biology of Blood and Marrow Transplantation
2025 - Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease
New England Journal of Medicine
2024 - Safety and Efficacy of Axatilimab in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)
Biology of Blood and Marrow Transplantation
2024 - Phase 1/2 evaluation of revumenib in patients with advanced colorectal cancer and other solid tumors.
Journal of Clinical Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Neeraj Agarwal, MD
Huntsman Cancer Institute
Josef Prchal, MD
Huntsman Cancer Institute
Ahmad Halwani, MD
Huntsman Cancer Institute
Talicia Savage, MD, PhD
Huntsman Cancer Institute
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”